α-Fetoprotein level-dependent early hepatitis B surface antigen decline during entecavir therapy in chronic hepatitis B with hepatitis flare | Zendy

WenJuei Jeng | Zendy; YiCheng Chen | Zendy; MingLing Chang | Zendy; YunFan Liaw | Zendy

Open Access

α-Fetoprotein level-dependent early hepatitis B surface antigen decline during entecavir therapy in chronic hepatitis B with hepatitis flare

Author(s) -

WenJuei Jeng,

YiCheng Chen,

MingLing Chang,

YunFan Liaw

Publication year - 2016

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkw019

Subject(s) - entecavir , hbsag , medicine , antigen , hepatitis b , hepatitis , virology , immunology , gastroenterology , chronic hepatitis , hepatitis b virus , virus , lamivudine

Hepatitis B surface antigen (HBsAg) reduction during nucleos(t)ide analogue therapy is related to ALT level. ALT reflects hepatocytolysis while α-fetoprotein (AFP) ≥100 ng/mL during hepatitis flare reflects more extensive hepatocytolysis (bridging hepatic necrosis). The impact of AFP levels on early HBsAg kinetics during entecavir therapy was investigated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research